Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...

Researchers found that patients with iRBD showed a higher number of shorter movements and immobility periods. HealthDay News — Automated analysis of two-dimensional (2D) camera recordings can improve ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products approved by the Food and Drug ...

Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs for Rhinosinusitis have a 75% phase ...

Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Perennial Allergic Rhinitis. According to GlobalData, Phase III drugs for Perennial Allergic Rhinitis ...

A 60-year-old woman presented with itchy, eczematous, and moderately exudative lesions on the scalp after 4 months' use of a galenic lotion of minoxidil 5% (minoxidil 5%, propylene glycol 15%, and ...